SPHINX31
SPHINX31 is a potent and selective SRPK1 inhibitor, with an IC50 of 5.9 nM. SPHINX31 inhibits phosphorylation of serine/arginine-rich splicing factor 1 (SRSF1) . SPHINX31 also decreases the mRNA expression of pro-angiogenic VEGF-A165a isoform. SPHINX31 can be used to research neovascular eye disease[1][2][3].
Product Specifications
CAS Number
1818389-84-2
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
SRPK; VEGFR
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer; Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/sphinx31.html
Purity
99.25
Solubility
DMSO : 15 mg/mL (ultrasonic)
Smiles
O=C(NC1=C(N2CCN(CC3=CC=CC=N3)CC2)C=CC(C(F)(F)F)=C1)C4=CC=C(O4)C5=CC=NC=C5
Molecular Formula
C27H24F3N5O2
Molecular Weight
507.51
Precautions
H302, H315, H319, H335
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Streptococcus pneumoniae, Common C-polysaccharide (MaxLight 490)
Streptococcus pneumoniae, Common C-polysaccharide (MaxLight 490)